FHC
BLRX

First Heartland Consultants’s BioLineRX BLRX Stock Holding History

First Heartland Consultants’s Portfolio BLRX Stock Details BLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-250
Closed -$27K – 373
2021
Q3 		$27K Hold
250
– – ﹤0.01% 386
2021
Q2 		$28K Hold
250
– – ﹤0.01% 382
2021
Q1 		$28K Buy
+250
New +$30.1K ﹤0.01% 386

Other funds holding BLRX

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PAM
PVG Asset Management Golden, Colorado $173M AUM 64.51% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
JF
Jump Financial Chicago, Illinois $7.5B AUM 33.9% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GWM
Geneos Wealth Management Englewood, Colorado $4.31B AUM 18.36% 1-Year Est. Return

First Heartland Consultants's BLRX Position: Q4 2021 in Review

First Heartland Consultants sold out of BioLineRX (BLRX) in Q4 2021, closing a stake of 250 shares — an estimated $27K sold.

First Heartland Consultants first reported a position in BLRX in Q1 2021 and held it in 3 quarters. The position peaked at $28K in Q2 2021. 30 funds tracked by Wall St. Rank hold BLRX as of Q4 2021.

  • First Heartland Consultants reported no remaining BioLineRX position as of Q4 2021 after selling out during the quarter.
  • First Heartland Consultants sold 250 BioLineRX shares in Q4 2021, an estimated $27K.
  • First Heartland Consultants first reported a position in BioLineRX in Q1 2021 and held it in 3 quarters.
  • First Heartland Consultants's BioLineRX position peaked at $28K in Q2 2021.
  • 30 funds tracked by Wall St. Rank held BioLineRX as of Q4 2021.

Based on First Heartland Consultants's 13F filing for Q4 2021, filed 11 Feb 2022.